Agenus Inc. (AGEN)
| Market Cap | 850.90M |
| Revenue (ttm) | 320.08M |
| Net Income (ttm) | 18.07M |
| Shares Out | 283.16M |
| EPS (ttm) | -0.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,136,440 |
| Open | 2.73 |
| Previous Close | 2.67 |
| Day's Range | 2.67 - 3.05 |
| 52-Week Range | 1.25 - 6.79 |
| Beta | 1.20 |
| Analysts | Buy |
| Price Target | 9.86 (+228.1%) |
| Earnings Date | Aug 9, 2022 |
About AGEN
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical tri... [Read more...]
Financial Performance
In 2021, Agenus's revenue was $295.67 million, an increase of 235.34% compared to the previous year's $88.17 million. Losses were -$23.93 million, -86.77% less than in 2020.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for AGEN stock is "Buy." The 12-month stock price forecast is 9.86, which is an increase of 228.12% from the latest price.
News
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
Agenus (AGEN) delivered earnings and revenue surprises of 26.09% and 11.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Agenus Provides Corporate Update and Second Quarter 2022 Financial Report
LEXINGTON, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers ...
Agenus to Participate at BTIG Biotechnology Conference
LEXINGTON, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and i...
Agenus Announces First Patient Dosed in Phase 1 Study of AGEN1571 (anti-ILT2) in Advanced Solid Tumors
Study will evaluate safety and tolerability of AGEN1571 as a single agent and in combination with botensilimab and balstilimab
Agenus to Provide Corporate Update and Second Quarter 2022 Financial Report
Conference Call on Tuesday, August 9, 2022 at 8:30 a.m. ET Conference Call on Tuesday, August 9, 2022 at 8:30 a.m. ET
Why Shares of Agenus Inc. Rose 10.1% on Tuesday
The company has a promising colon cancer therapy.
3 Amazing Stocks Under $10
Here's why we like SeaSpine, Recursion Pharmaceuticals, and Agenus.
Agenus to Participate at William Blair's Biotech Focus Conference
LEXINGTON, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and i...
Why Agenus Stock Is Soaring Today
The company reported encouraging results from an early study of its experimental colorectal cancer combo therapy.
Agenus Touts 'Unprecedented Activity' For Botensilimab/Balstilimab Combo In Colorectal Cancer
Agenus Inc (NASDAQ: AGEN) has announced expanded data from the Phase 1b study of botensilimab and balstilimab in patients with microsatellite stable colorectal cancer. The data demonstrate that the comb...
Agenus Shows Unprecedented Activity for Botensilimab/Balstilimab Combination in Microsatellite Stable Colorectal Canc...
LEXINGTON, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and i...
Agenus to Host Investor Webcast to Review Late-Breaking Botensilimab and Balstilimab Data Presented at ESMO World GI ...
LEXINGTON, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and i...
GSK's RSV vaccine candidate for older adults, containing Agenus' QS-21 STIMULON™ as part of GSK's AS01 adjuvant, repo...
LEXINGTON, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapies and adjuvants designed to activate the immune response to ca...
Agenus Advances Portfolio with 6 Clinical Collaborations
LEXINGTON, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers a...
Agenus Announces Virtual Annual Shareholders Meeting
LEXINGTON, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and in...
Agenus to Participate at Jefferies Healthcare Conference
LEXINGTON, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and in...
Agenus Announces Late-Breaking Oral Presentation at ESMO-GI and Strategies to Advance Botensilimab
LEXINGTON, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response to cancers and i...
3 Biotech Stocks With a Cash Pile Higher Than Their Valuations
Our roundtable found three biotechs with a nice cash cushion.
Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates
Agenus (AGEN) delivered earnings and revenue surprises of 34.48% and 49.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Agenus Corporate Update and First Quarter 2022 Financial Report
LEXINGTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers a...
Agenus to Provide Corporate Update and First Quarter 2022 Financial Report
Conference Call on Tuesday, May 10, 2022 at 8:30 a.m. ET Conference Call on Tuesday, May 10, 2022 at 8:30 a.m. ET
Why Adaptimmune Therapeutics, Agenus, and Sorrento Therapeutics Popped Today
Regeneron's buyout of Checkpoint Pharmaceuticals is sparking a rally among clinical-stage cancer research companies today.
Agenus Presents Data on AGEN1571 (anti-ILT2) at AACR and Announces IND Clearance
LEXINGTON, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response to cancers and...
Agenus' CD137 Agonist (AGEN2373) Advances in the Clinic, Triggering Milestone Payment from Gilead
LEXINGTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response to cancers and...
Targovax ASA and Agenus announce collaboration on mutant KRAS cancer vaccine adjuvanted with QS-21 STIMULON™
LEXINGTON, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate i...